14 Jun 2024

Tempus

Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.

Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.

NewsHeat chart

Week
Month
Year

Media news
Corp news

Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

Valuation
Share Price
Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round

Funding Amount

Post-Money Valuation

Share Price

Growth Capital20 Oct, 2022

***

Series G10 Dec, 2020

***

Series G13 Mar, 2020

***

Series F30 May, 2019

***

Series E29 Aug, 2018

***

Series D20 Mar, 2018

***

Series C25 Sep, 2017

***

Series B17 Apr, 2017

***

Series B22 Nov, 2016

***

Series B20 Jun, 2016

***

Series A21 Sep, 2015

***

*** - To view the data, please log into your account or create a new one.

News related to Tempus167

Sort by

Tempus

Sep 6, 2024 •Show on chart

Tempus Announces Real World Data Collaboration with BioNTech - Tempus

The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and ...

Tempus https://www.tempus.com/news/tempus-announces-real-world-data-collaboration-with-biontech/

Tempus

Aug 30, 2024 •Show on chart

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, N...

Tempus https://www.tempus.com/news/tempus-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference/

Tempus

Aug 16, 2024 •Show on chart

World Clinical Biomarkers & CDx Summit 2024 - Tempus

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to attend the 14th annual World CB & CDx Summit and present how Tempus can support strategic CDx development through to comme...

Tempus https://www.tempus.com/events/world-cb-cdx-2024/

Tempus

Aug 9, 2024 •Show on chart

Tempus Evening Reception: NSGC 2024 - Tempus

Join Tempus at Sidecar Patio & Oyster Bar to explore our cutting-edge advancements in precision medicine. Mingle with industry peers while enjoying local food and refreshments in the picturesque New Orleans courtyard....

Tempus https://www.tempus.com/events/tempus-evening-reception-nsgc-2024/

Tempus

Aug 2, 2024 •Show on chart

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2 - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable bio...

Tempus https://www.tempus.com/news/tempus-next-launches-new-algorithm-to-close-care-gaps-in-guideline-directed-ihc-testing-starting-with-her2/